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Abstract
The fate of dietary protein in the gut is determined by microbial and host digestion and utilization. Fermentation of
proteins generates bioactive molecules that have wide-ranging health effects on the host. The type of protein can
affect amino acid absorption, with animal proteins generally being more efficiently absorbed compared with plant
proteins. In contrast to animal proteins, most plant proteins, such as pea protein, are incomplete proteins. Pea protein
is low in methionine and contains lower amounts of branched-chain amino acids (BCAAs), which play a crucial role
in muscle health. We hypothesized that probiotic supplementation results in favorable changes in the gut microbiota,
aiding the absorption of amino acids from plant proteins by the host. Fifteen physically active men (24.2 ± 5.0 years;
85.3 ± 12.9 kg; 178.0 ± 7.6 cm; 16.7 ± 5.8% body fat) co-ingested 20 g of pea protein with either AminoAlta™, a
multi-strain probiotic (5 billion CFU L. paracasei LP-DG® (CNCM I-1572) plus 5 billion CFU L. paracasei LPC-
S01 (DSM 26760), SOFAR S.p.A., Italy) or a placebo for 2 weeks in a randomized, double-blind, crossover design,
separated by a 4-week washout period. Blood samples were taken at baseline and at 30-, 60-, 120-, and 180-min
post-ingestion and analyzed for amino acid content. Probiotic administration significantly increased methionine,
histidine, valine, leucine, isoleucine, tyrosine, total BCAA, and total EAA maximum concentrations (Cmax) and
AUC without significantly changing the time to reach maximum concentrations. Probiotic supplementation can be an
important nutritional strategy to improve post-prandial changes in blood amino acids and to overcome compositional
shortcomings of plant proteins. ClinicalTrials.gov Identifier: ISRCTN38903788
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Introduction
Lactobacillus paracasei strains have been isolated from the
intestinal and reproductive tracts of humans and animals and
numerous food products such as raw milk, plants, or
fermented foods [1]. There are currently no clinical trials on
the combination of L. paracasei LP-DG® and L. paracasei
LPC-S01; however, the individual strains have been studied
for various health applications. Probiotic L. paracasei LP-
DG® (CNCM I-1572) can survive gastrointestinal transit in
children [2] and healthy adults [3] and has been shown to be
able to modulate gut microbiota structure/function and im-
mune health in healthy adults [4], patients with irritable bowel
syndrome (IBS) [5, 6], and diverticular disease [7–10]. Similar
to L. paracasei LP-DG® (CNCM I-1572), L. paracasei LPC-
S01 (DSM 26760) has been shown to colonize the human gut
of healthy adults [11]. Through optimizing gut microbiota
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composition, probiotics have been linked to improve nutrient
absorption, including protein utilization [12].
Different types and quality of dietary protein can affect
amino acid absorption following protein supplementation.
Compared with animal protein sources, plant protein
sources, with the exception of soy protein, are incomplete
proteins lacking in one or more essential amino acids.
Plant proteins contain less branched-chain amino acids
(BCAAs), especially leucine [13], one of the crucial ami-
no acids for muscle health, especially the activation of
muscle protein synthesis (MPS) [14]. In addition, plant
proteins differ in absorption kinetics and the amount of
amino acids absorbed by the host. Therefore, there is an
interest in nutritional strategies to raise the blood amino
acid concentrations after ingesting a plant protein source
to overcome compositional shortcomings.
The fate of dietary protein in the gut is determined by
microbial and host digestion and utilization. Dietary protein
is cleaved into polypeptides by proteases at low pH in the
stomach. Further degradation in the intestine by luminal pro-
teases and membrane bound peptidases results in the forma-
tion of peptides and amino acids. Amino acids enter the cell
via various transmembrane transport proteins, amino acid
transporters, while di- and tripeptides are absorbed into the
intestinal cells via the mammalian proton-coupled peptide
transporter PEPT1. In the cytosol, peptides are mostly degrad-
ed leaving the cell as amino acids. Bacterial proteolytic fer-
mentation in the gut competes with host digestion, significant-
ly contributing to the metabolite pool in the large intestine and
contributing to host amino acid balance in the small intestine.
Microbial protein fermentation alters the gut microbiota com-
position and generates a diverse range of bioactive molecules
which exert wide-ranging host effects [15].
While lactic acid bacteria (LAB) have proteases and pepti-
dases that provide the bacteria with free amino acids for optimal
growth, they are not classified as strongly proteolytic bacteria.
The role of LAB such as L. paracasei on protein digestion and
absorption of amino acids by the host is currently unknown.
The purpose of this study was to investigate the individual
and potential additive or synergistic effects of L. paracasei
LP-DG® (CNCM I-1572) and/or L. paracasei LPC-S01
(DSM 26760) on the in vitro digestion of different plant pro-
tein sources, followed by a human study investigating blood
amino acid concentrations after co-administration of plant
protein and probiotics.
Materials and Methods
In Vitro Tests
In vitro proteolytic effects of the two probiotic strains
towards different plant protein sources have been
investigated by incubating suspensions of either pea or
rice protein isolates with the probiotic bacterial strains,
in the presence and in the absence of porcine pepsin
(EC 3.4.23.1; Sigma-Aldrich, Milan, Italy) and pancreatin
(Sigma-Aldrich, Milan, Italy). In particular, 0.8 mL of
protein isolate suspension (10 g/L) was mixed with
0.02 mL of porcine gastric pepsin solution (2 g/L in wa-
ter). After 1-h incubation at 37 °C under mixing, the pH
was adjusted to ≈ 8.0 by adding 1 M Tris base, and
0.2 mL pancreatin from porcine pancreas (2 g/L in
0.1 M Tris-HCl buffer, pH 7.5; EC 232-468-9) were
added. Pancreatin digestion was carried out for 3 h in
the absence or in the presence (when appropriate) of
0.1 mL of probiotic cells (250 g/L in 0.1 M Tris-HCl
buffer, pH 7.5). To address the proteolytic activity of the
bacteria alone on the various substrates, reaction mixtures
were prepared by using the probiotic strains either indi-
vidually or in combination, but without adding any prote-
ases. Also, as a negative control, 0.1 mL bacterial cell
suspensions were mixed with 0.1 M Tris-HCl buffer, pH
7.5.
Peptides released upon proteolysis in all tested conditions
were assessed by adding to an appropriate aliquot of each
reaction mixture trichloroacetic acid (TCA) up to a final
10% amount. After centrifuging at 10000×g for 25 min at
room temperature, the absorbance at 280 nm of the superna-
tant provides the amount of soluble peptides.
For SDS-PAGE analysis, adequate amounts of the different
reaction mixtures at various times of incubation were diluted
(1/1, v/v) with Laemmli denaturing buffer (0.125MTris–HCl,
pH 6.8; 50% glycerol; 1.7% SDS; 0.01% bromophenol blue;
1% 2-mercaptoethanol) and heated at 100 °C for 10 min.
SDS-PAGE was carried out on a 12% monomer gel, by using
aMiniProtein apparatus (Bio-Rad, Richmond, VA, USA), and
gels were Coomassie Blue-stained.
Aliquots of the various reaction mixtures were treated
with 0.1% trifluoroacetic acid (TFA) and subsequently
centrifuged at 12000×g for 20 min. A 0.2 mL aliquot of
the soluble material was loaded onto a Symmetry C18
column (300 Å; 3.5 μm; 2.1 mm × 50 mm; Waters,
Milan, IT), previously equilibrated with 0.1% TFA in dis-
tilled water, and eluted at a flow rate of 0.8 mL/min, with
a linear gradient starting 5 min after injection up to 60%
(v/v) acetonitrile, in the presence of 0.1% TFA. The chro-
matographic separation was carried out by a Waters™ 626
system and equipped with a Waters™ 2487 dual wave-
length detector (Waters, Milan, Italy). Data at 220 nm and
at 280 nm were recorded and elaborated by using the
software Empower Pro (Waters, Milan, Italy). Results
are expressed as total peak area measured at 220 nm that
include the peptides that do not contain aromatic residuals
that were quantified measuring the absorbance at 280 nm
of the supernatant after TFA treatment.
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Human Clinical Study
This multicenter study was conducted at Texas Christian
University (TCU), Fort Worth, TX, USA, and the University
of Mary Hardin-Baylor (UMHB), Belton, TX, USA, in accor-
dance with the Declaration of Helsinki guidelines and regis-
tered with the ISRCTN registry (ISRCTN38903788). All the
procedures were approved by the Institutional Review Board
of Texas Christian University (IRB approval: 1707-080-1707)
and University of Mary Hardin-Baylor (IRB approval: 44).
Despite this being a multicenter trial, all blood analyses were
sent to Heartland Assays, Iowa State University Research
Park, Ames, IA, USA, to eliminate the risk of a study site
effect.
Participants
Fifteen healthy men (TCU = 10; UMHB = 5; n = 15) between
the ages of 18–35 years were recruited to participate in this
study (Table 1). In order to qualify for this study, participants
needed to have normal body weight (body mass index (BMI)
of 19–24.99 kg/m2) and be recreationally active (according to
the American College of Sports Medicine Guidelines).
Subjects were not allowed to consume any nutritional or er-
gogenic supplement known to affect measures of the current
study for the prior 6 weeks, including probiotics, prebiotics,
and digestive enzymes. Exclusion criteria included any indi-
vidual who was treated for or diagnosed with a gastrointesti-
nal, cardiac, respiratory, circulatory, musculoskeletal, meta-
bolic, immune, autoimmune, psychiatric, hematological, neu-
rological, or endocrinological disorder. Participants who were
determined to not be weight stable defined as measured body
mass deviating by 2% or more, and participants who were not
willing to abstain from alcohol, nicotine, and caffeine for 12 h
prior to each visit were excluded. Participants who met the
necessary inclusion criteria were further encouraged not to
change their current physical activity levels and to refrain
from exercise for 24 h before starting the clinical trial. At
TCU, participants were randomized via the RAND function
in Microsoft Excel. Of the 10 participants completed at TCU,
3 completed the treatment first, while the other 7 completed
the placebo. At UMHB, participants were randomized using
Random.org. Of the 5 participants completed at UMHB, all
completed the treatment first and placebo second.
Experimental Protocol
A randomized, double-blind, crossover pilot study was per-
formed to assess the amino acid concentration in the blood
after the administration of a plant protein with or without co-
administration of a probiotic supplement. Prior to beginning
the study, all participants signed an IRB-approved informed
consent document and completed a health history question-
naire to determine study eligibility. Two supplementation pe-
riods that each spanned 2 weeks were completed and separat-
ed by a washout period of 4 weeks. For each study visit, all
participants reported to the laboratory between 06:00 and
10:00 h after observing an 8–10-h fast. Daily diet was record-
ed, and subjects were asked to repeat the same diet for 2 weeks
leading up to the second experimental testing. Participants
were randomly assigned to ingest either a single daily 20-g
dose of a pea protein plus placebo or a single daily 20-g dose
of a pea protein plus probiotic. Upon arrival for each study
visit, participants had their resting heart rate, blood pressure,
body mass, height, and body fat measured using skinfold. The
occurrence of adverse events was recorded throughout com-
pletion of the supplementation and study visits. Adverse
events were collected through spontaneous reporting by the
study participants, clinical evaluation, or interaction of a re-
search team member with a study participant. Subjects rested
semi-supine for placement of a Teflon catheter into an
antecubital vein for multiple blood sampling. The catheter
was kept patent by flushing with 3 ml of 0.9% sodium chlo-
ride. Following baseline sampling, participants ingested their
respective supplement. Thereafter, blood samples were taken
at 30-, 60-, 120-, and 180-min post-ingestion (Table 2).
Subsequently, a 4-week washout period was implemented,
followed by the opposite condition. Whole blood was collect-
ed and transferred into Becton Dickinson (BD) 8.5 ml tubes
(BD Vacutainer SST) for obtaining serum and BD 10.0 ml
(Vacutainer Sodium Heparin) tubes for obtaining plasma and
subsequently centrifuged at 1500×g for 15 min at 4 °C.
Resulting serum and plasma were then aliquoted and stored
at − 80 °C until subsequent analyses.
Supplementation
Participants co-administered 20 g of protein (vegetable protein
isolated from yellow pea (Pisum sativum), NUTRALYS®
S85F, Roquette Freres S.A., France) with either 10 billion
CFU of a multi-strain probiotic (5 billion CFU L. paracasei
LP-DG® (CNCM I-1572) and 5 billion CFU L. paracasei
LPC-S01 (DSM 26760), AminoAlta™, SOFAR S.p.A.,
Italy) or a placebo (maltodextrin, Glucidex® 12, Roquette
Freres S.A., France), in a randomized order. The study mate-
rials were provided in a dual chamber sachet, separating the
protein from the probiotic or placebo until the time of con-
sumption. Subjects were instructed to open the pouch, mix the
Table 1 Subject
characteristics at baseline
(n = 15)
Age (years) 24.2 ± 5.0
Height (cm) 178.0 ± 7.6
Weight (kg) 85.3 ± 12.9
Body Fat (%) 16.7 ± 5.8
Data is presented as means ± standard
deviation
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ingredients with 473 ml of their favorite non-protein contain-
ing beverage, and consume the product immediately. On
weekdays, subjects reported to the lab daily and consumed
the study materials in front of the researchers to ensure com-
pliance. On Fridays, subjects received two additional sachets
to be taken during the weekend. Study material identity and
potency was verified by an independent lab (for probiotic,
Covance Laboratories Inc., Madison, WI, USA; for protein
content and amino acid composition, Table 3, Eurofins,
Madison, WI, USA) after the completion of the study and
blinded analysis of the results.
Amino Acid Analysis
EZ:faast® amino acid analysis kits (Phenomenex, Torrance,
CA) were used for liquid chromatographic analysis of amino
acids using tandem-mass spectrometry (LC/MS/MS) and
electrospray ionization (ESI). The procedure consisted of sol-
id phase extraction of 25 μl of plasma with internal standards
by a sorbent tip attached to a syringe with an eluting solvent (a
3:2 mixture of sodium hydroxide with 77% n-propanol and
23% 3-picoline). The free amino acids were then derivatized
by adding a mixture of 17.4% propyl chloroformate, 11%
isooctane, and 71.6% chloroform. The resulting mixture was
vortexed and allowed to sit at room temperature for 1 min,
followed by liquid-liquid extraction with isooctane. Fifty mi-
croliters of the organic layer were removed, dried under nitro-
gen gas, and suspended in the HPLC run solvents before being
injected into the LC/MS/MS. Chromatographic separation of
the derivatized amino acids was conducted on an EZ:faast
amino acid analysis-mass spectrometry column (250 ×
2.0 mm i.d., 4 μm) using an Agilent 6460 triple quadrupole
LC/MS/MS system (Santa Clara, CA). Ten millimeters of am-
monium formate in water with 0.2% formic acid (mobile
phase A) and 10 mM ammonium formate in methanol with
0.2% formic acid (mobile phase B) were used as solvent sys-
tem with gradient conditions of 68%B at 0 min to 83%B over
13 min with a flow rate of 0.25 ml/min. Amino acids and
internal standard data were collected using the dynamic mul-
tiple reaction monitoring mode using MassHunter acquisition
software (Agilent, Santa Clara, CA). MassHunter
Table 3 Amino acid
profile of the study
material (Eurofins
Certificate of Analysis,
2,696,852–0, November
20, 2019)
Amino acid [mg/g of protein]
Alanine 43
Arginine 88
Aspartic acid 117
Cysteine 9
Glutamic acid 167
Glycine 41
Histidine 25
Isoleucine 48
Leucine 83
Lysine 74
Methionine 12
Phenylalanine 54
Proline 45
Serine 50
Threonine 40
Tryptophan 10
Tyrosine 39
Valine 51
Table 2 Study design
Screening and
consent
Baseline testing Day 1–14 Day 15 Day 16–
43
Day 44–57 Day 58
Screening Body height and
weight
2 weeks of
supplementation +
dietary recording
Body height and weight 4 weeks
of
wash-
out
2 weeks of
supplementation +
dietary recording
Body height and weight
Informed
consent
Vitals Supplementation
adherence check
Supplementation
adherence check
Demographics Instructions for
supplementa-
tion
Dietary recording check Dietary recording check
Health history Instructions for
dietary
recording
Adverse event check Adverse event check
Exercise
history
Dietary
restrictions
Fasting blood draw Fasting blood draw
Body height
and weight
Ingestion of plant protein
with or without a
probiotic
Ingestion of plant protein
with or without a
probiotic
Vitals Subsequent blood draws
(30, 60, 120, 180 min)
Subsequent blood draws
(30, 60, 120, 180 min)
Randomization
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Quantitation software was used to quantitate the unknown
plasma samples based on best fit standard curves.
Statistical Analysis
The area under the concentration vs. time curve (AUC) was
calculated for each of the 22 amino acids, as well as BCAAs,
EAAs, and total amino acids, via the linear trapezoidal rule
and using all available time points. Cmax was defined as the
maximum observed concentration, and Tmax was the time at
which Cmax was reached. AUC values were compared be-
tween conditions via paired sample t tests. A p value < 0.05
was considered statistically significant. Analyses were per-
formed in R (v. 3.6.1) using the PKNCA package. Cohen’s
d effect sizes were calculated as the mean difference between
conditions (i.e., protein plus probiotic minus protein) divided
by the pooled standard deviation. Percent differences between
treatments were calculated as the mean difference between
conditions minus the value in the Protein condition times
one hundred. Results are expressed as mean ± standard devi-
ation (SD) unless otherwise noted. In vitro digestion data are
the results of three independent determinations, each per-
formed in triplicate. Analysis of variance of the in vitro diges-
tion data was performed adopting the least significant differ-
ence (LSD). Data were analyzed using Statgraphics XV, ver-
sion 15.1.02 (StatPoint, Warrenton, VA, USA).
Results
In Vitro Tests
SDS-PAGE analysis of the 8 different conditions showed that
the combination of pepsin and pancreatin, with or without the
individual or combined strains, no longer contained intact
proteins (Table 4). In contrast, the individual strain alone or
in combination did not show evident proteolytic activity.
Analysis by RP-HPLC showed that the addition of the probi-
otic strains resulted in different peptides compared with diges-
tive enzymes alone. L. paracasei LP-DG® showed a greater
increase with rice protein in comparison with L. paracasei
LPC-S01, whereas the combination of two strains showed a
synergistic effect with pea protein. Based on the outcome of
the in vitro tests, the combination of L. paracasei LP-DG®
and L. paracasei LPC-S01 with pea protein was chosen for
the human clinical study, to investigate if the probiotic strains
can increase amino acid appearance in the blood, when co-
administered with plant proteins.
Human Data
L. paracasei LP-DG® (5 billion CFU per day), L. paracasei
LPC-S01 (5 billion CFU per day), and pea protein
supplementation (20 g per day) were safe in healthy adults.
No adverse events were observed during the duration of the
clinical study in either group.
Probiotic administration significantly increased area under
the curve (AUC) (Table 5) for methionine (+ 20.0%), histidine
(+ 40.4%), valine (+ 21.5%), leucine (+ 23.3%), isoleucine (+
26.0%), tyrosine (+ 16.0%), total BCAA (+ 22.8%), and total
EAA (+ 16.0%) concentrations.
Probiotic administration significantly increased methionine
(+ 16.3%), histidine (+ 49.2%), valine (+ 24.7%), leucine (+
25.2%), isoleucine (+ 26.1%), tyrosine (+ 11.6%), total
BCAA (+ 26.8%), and total EAA (+ 15.6%) maximum con-
centrations (Table 6).
Probiotic administration did not alter the time to reach the
maximum concentration (Table 7).
Discussion
Growing transition to more plant-based, whole-food, sustain-
able diets raised questions about the protein adequacy of veg-
etarian and vegan diets. In addition, a reduction of animal
protein intake, in particular meat consumption, has recently
become more prevalent in Western countries. Protein intake is
usually the highest in meat-eaters, followed by fish-eaters,
lacto-ovo vegetarians, and vegans [16]. Insufficient protein
intake from vegetarian diets may occur if the diets are low in
protein-rich foods such as legumes, nuts, or seeds; however,
there is currently no evidence that a balanced vegetarian diet
provides inadequate total protein intakes [16]. Plant proteins
differ in digestibility and amino acid composition from animal
proteins. Specifically, plant proteins such as pea or rice are
lower in leucine and total BCAA content, amino acids that
have been linked to muscle health by activating MPS [17].
In contrast to omnivores, people following a vegetarian diet
have lower circulating serum BCAA concentrations, which
have been linked to lower dietary intake of BCAAs and also
to changes in the gut microbiota composition resulting in up-
regulation of the gut microbial pathway for the degradation of
BCAAs [18].
Probiotics function predominately in the large intestine.
There is currently no evidence that amino acids liberated from
bacterial fermentation in the large intestine alter plasma amino
acid concentrations of the host; however, certain probiotic
strains have proteolytic properties and have been linked to
an increased production of digestive enzymes and subsequent-
ly improved host protein utilization [12]. Thus, the purpose of
this study was to investigate the individual and potential ad-
ditive or synergistic effects of L. paracasei LP-DG® and/or
L. paracasei LPC-S01 on the in vitro digestion of different
plant protein sources, in conjunction with a human study in-
vestigating post-prandial changes in blood amino acids in re-
sponse to a 20 g protein bolus, with or without the probiotic.
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Table 5 Individual amino acids,
total BCAA, total EAA and total
amino acid area under the curve
(AUC)
AUC [μmol /L • 180 min]
Amino acid Protein plus probiotic Protein Protein plus probiotic vs. protein
Mean SD Mean SD p value (t
test)
Difference
(%)
Effect size
(d)
Arginine 14,490.3 4677.7 13,954.3 6438.0 0.585 3.8 0.10
Glutamine 90,876.4 21,491.3 87,569.0 25,645.0 0.649 3.8 0.14
Citrulline 3936.4 1411.6 3922.3 1906.1 0.967 0.4 0.01
Serine 17,569.1 4194.0 17,464.6 6513.0 0.942 0.6 0.02
Asparagine 13,305.5 3226.3 12,212.4 3774.1 0.337 9.0 0.31
Glycine 33,083.9 9728.7 32,626.4 10,309.8 0.874 1.4 0.05
Threonine 22,917.0 4289.4 21,905.7 6917.8 0.621 4.6 0.18
Alanine 56,904.7 13,342.8 53,750.8 20,418.2 0.496 5.9 0.18
Ornithine 10,060.4 3334.2 9793.9 3678.8 0.693 2.7 0.08
Methionine 3558.9 1462.0 2966.9 1245.0 0.007* 20.0 0.44
Proline 43,142.9 10,833.0 42,124.2 19,636.2 0.780 2.4 0.06
Lysine 36,177.2 5057.1 35,387.7 10,758.1 0.759 2.2 0.09
Aspartic acid 711.7 259.4 591.1 277.9 0.125 20.4 0.45
Histidine 14,388.0 4519.9 10,248.1 3983.4 0.009* 40.4 0.97
Valine 65,216.4 17,782.9 53,682.1 17,525.3 0.013* 21.5 0.65
Glutamic acid 6523.0 3703.0 6384.9 3079.4 0.849 2.2 0.04
Tryptophan 13,056.3 4319.6 12,078.2 3535.2 0.276 8.1 0.25
Leucine 26,443.5 10,874.2 21,447.6 10,701.1 0.006* 23.3 0.46
Phenylalanine 8879.6 2629.0 8061.8 3371.5 0.086 10.1 0.27
Isoleucine 19,048.2 6642.5 15,116.5 5961.5 0.017* 26.0 0.62
Cysteine 3016.2 932.8 3024.9 1468.0 0.978 − 0.3 − 0.01
Tyrosine 10,790.8 3532.4 9306.0 3923.5 0.009* 16.0 0.40
Total BCAA 110,886.8 33,142.0 90,304.5 33,001.5 0.008* 22.8 0.62
Total EAA 210,115.0 41,010.5 181,071.7 54,739.9 0.005* 16.0 0.60
Total amino
acids
515,152.2 79,378.2 474,059.9 139,979.5 0.136 8.7 0.36
Table 4 Analysis of overall
proteolysis by RP-HPLC
separation
Treatment Rice Pea
Area (*106) Δ, % Area (*106) Δ, %
Absorbance at 220 nm
Pepsin + pancreatin 78.2 ± 0.10 107 ± 0.60
Pepsin + pancreatin + L. paracasei LP-DG 80.2 ± 0.15* + 2.6 107 ± 0.50 0
Pepsin + pancreatin + L. paracasei LPC-S01 78.4 ± 0.21 + 0.3 111 ± 0.80* + 3.7
Pepsin + pancreatin + LP-DG + LPC-S01 80.6 ± 0.18* + 3.1 114 ± 0.70** + 6.5
Absorbance at 280 nm
Pepsin + pancreatin 5.1 ± 0.10 11.9 ± 0.06
Pepsin + pancreatin + L. paracasei LP-DG 5.4 ± 0.09* + 5.9 12.0 ± 0.08 + 0.8
Pepsin + pancreatin + L. paracasei LPC-S01 5.2 ± 0.08 + 2.0 12.2 ± 0.02* + 2.5
Pepsin + pancreatin + LP-DG + LPC-S01 5.4 ± 0.10* + 5.9 12.6 ± 0.07** + 5.6
Data is presented as means ± standard deviation
*Significantly different from control (p < 0.05)
**Significantly different from control and single strain (p < 0.05)
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The primary findings of the in vitro data showed increased
proteolysis and a synergistic effect with the combination of
L. paracasei LP-DG® and L. paracasei LPC-S01 (+ 6.5% at
220 nm; + 5.6% at 280 nm) compared with either strain alone
for pea protein. Similar to the in vitro data, results from the
human clinical trial showed increases in AUC for total BCAA
(+ 22.8%) and total EAA (+ 16.0%) concentrations after
2 weeks of probiotic supplementation. Moreover, increases
in leucine (+ 23.3%), isoleucine (+ 26.0%), valine (+ 21.5%),
and total EAA (+ 16.0%) absorption suggest a potential for
administering L. paracasei LP-DG® and L. paracasei LPC-
S01 for optimization of amino acid absorption following pea
protein consumption. Taken together, these data illustrate that
this could be a strategy to enhance absorption levels of plant-
based proteins and have implications on increasing protein
utilization following the post-absorptive period in the human
gut.
For buildingmuscle mass and for maintaining muscle mass
through a positive muscle protein balance, an overall daily
protein intake in the range of 1.4–2.0 g protein/kg body
weight/day (g/kg/d) is sufficient for most exercising individ-
uals, and acute protein doses should strive to contain 1700 to
3000 mg of leucine, in addition to a balanced array of 10–12 g
of EAAs [14]. EAAs play a critical role for achieving maximal
rates of MPSmaking protein sources that are rich in EAAs the
preferred sources of protein [14]. Amino acid analysis of the
study material confirmed the relatively low leucine content
(approx. 8%) of pea protein, in comparison with animal pro-
teins such as whey protein, containing approx. 10–11% of
leucine [19]. When compensating for the low leucine content
by using large isonitrogenous doses (48–50 g of protein), rice
[19] and pea protein [20] have been shown to be as effective as
whey protein in increasing lean body mass and strength when
combined with resistance exercise; however, the ability of
standard protein doses (18–24 g of protein) has not been stud-
ied yet. Increasing leucine AUC concentration by 23% and
total EAA concentrations by 16% by co-ingestion of
probiotics helps to overcome the compositional shortcomings
Table 6 Individual amino acids,
total BCAA, total EAA, and total
amino acid maximum
concentration (Cmax)
Cmax [μmol/L]
Amino acid Protein plus
probiotic
Protein Protein plus probiotic vs. protein
Mean SD Mean SD p value (t test) Difference (%) Effect size (d)
Arginine 102.4 30.9 106.6 42.9 0.556 − 3.9 − 0.11
Glutamine 601.7 131.8 599.9 131.2 0.974 0.3 0.01
Citrulline 26.4 9.7 27.4 10.5 0.580 − 3.6 − 0.10
Serine 128.3 28.4 130.4 47.5 0.860 − 1.6 − 0.05
Asparagine 101.3 22.6 96.1 31.0 0.602 5.5 0.19
Glycine 228.3 56.7 237.3 66.5 0.625 − 3.8 − 0.15
Threonine 161.9 30.5 159.2 51.0 0.861 1.7 0.06
Alanine 414.6 148.2 389.6 135.3 0.418 6.4 0.18
Ornithine 72.8 23.4 72.0 23.7 0.881 1.2 0.04
Methionine 23.2 8.9 19.9 6.3 0.008* 16.3 0.42
Proline 318.7 129.1 323.0 176.2 0.905 − 1.3 − 0.03
Lysine 276.0 45.9 266.0 70.5 0.627 3.7 0.17
Aspartic acid 7.3 3.6 5.9 3.6 0.208 22.7 0.37
Histidine 110.0 59.1 73.7 24.5 0.048* 49.2 0.80
Valine 490.5 174.5 393.4 94.2 0.034* 24.7 0.69
Glutamic acid 50.4 24.3 51.9 22.5 0.740 −3.0 −0.07
Tryptophan 90.8 24.7 88.7 19.7 0.796 2.4 0.10
Leucine 200.7 80.3 160.3 71.6 0.043* 25.2 0.53
Phenylalanine 57.6 16.8 54.8 18.9 0.252 5.2 0.16
Isoleucine 149.4 46.8 118.4 41.6 0.020* 26.1 0.70
Cysteine 19.5 5.3 19.8 7.5 0.832 − 1.8 − 0.06
Tyrosine 70.6 23.2 63.3 22.6 0.014* 11.6 0.32
Total BCAA 833.8 237.5 657.8 192.6 0.009* 26.8 0.81
Total EAA 1512.6 315.7 1308.2 301.3 0.022* 15.6 0.66
Total amino acids 3566.6 586.2 3389.4 818.6 0.371 5.2 0.25
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of plant proteins and could help to elevate BCAA levels in the
blood to comparable levels of animal proteins, thereby poten-
tially removing the need to increase the dose of plant proteins
to achieve similar benefits of protein supplementation onmus-
cle health. In addition to increasing the effects of resistance
training on MPS, protein rich diets are used for weight man-
agement and weight loss during calorie-restricted diets. The
total amount of muscle mass is the sum of MPS and muscle
protein breakdown (MPB). A net positive muscle protein bal-
ance can be achieved ifMPS is greater thanMPB [21]. During
energy restriction, MPB increases, resulting in a loss of fat-
free mass, particularly if rates of weight loss exceed 1.0%
body mass loss per week [22]. Higher protein intakes (2.3–
3.1 g/kg/d) may be needed to maximize the retention of lean
body weight [14] and promotion of fat loss [23] in resistance
trained subjects during hypocaloric periods. Plant proteins
with the addition of probiotics might be more effective in
maintaining muscle mass during calorie-restricted diets, due
to the greater increase in hyperaminoacidemia, especially in
plasma leucine levels that stimulate MPS [21].
Athletes have varying gut microbiota compositions that
appear to reflect the activity level of the host in comparison
with sedentary people, with the differences linked primarily to
the volume of exercise and amount of protein consumption
[24]. The probiotic strains used in this study have been shown
to increase absorption of key nutrients of specific importance
to athletes, such as amino acids from protein. In addition,
probiotics offer various health benefits for active people
[25], such as improving the integrity of the gut-barrier func-
tion [26], and the administration of selected anti-inflammatory
probiotic strains has been linked to improved recovery from
muscle-damaging exercise [27]. Immune health in athletes is
compromised with excessive training load, psychological
stress, disturbed sleep, and environmental extremes, all of
which can contribute to an increased risk of respiratory tract
infections [28]. Approximately 70% of the immune system is
Table 7 Individual amino acids,
total BCAA, total EAA, and total
amino acid time to maximum
concentration (Tmax)
Tmax [min]
Amino acid Protein plus
probiotic
Protein Protein plus probiotic vs. protein
Mean SD Mean SD p value (t test) Difference (%) Effect size (d)
Arginine 58.0 41.6 40.0 14.6 0.057 45.0 0.58
Glutamine 54.0 41.2 60.0 56.7 0.748 − 10.0 − 0.12
Citrulline 56.0 46.6 48.0 49.2 0.546 16.7 0.17
Serine 52.0 40.0 40.0 29.3 0.271 30.0 0.34
Asparagine 58.0 43.1 46.0 33.8 0.395 26.1 0.31
Glycine 70.0 55.2 52.0 56.1 0.398 34.6 0.32
Threonine 62.0 51.3 50.0 40.4 0.458 24.0 0.26
Alanine 78.0 54.1 56.0 49.3 0.294 39.3 0.43
Ornithine 72.0 45.1 52.0 33.0 0.096 38.5 0.51
Methionine 48.0 42.1 38.0 13.7 0.388 26.3 0.32
Proline 66.0 53.4 56.0 54.2 0.632 17.9 0.19
Lysine 50.0 40.4 54.0 44.2 0.784 − 7.4 − 0.09
Aspartic acid 46.0 35.6 50.0 43.4 0.774 − 8.0 − 0.10
Histidine 62.0 51.3 44.0 43.7 0.246 40.9 0.38
Valine 60.0 40.9 58.0 53.7 0.914 3.4 0.04
Glutamic acid 42.0 37.3 74.0 69.8 0.088 − 43.2 − 0.57
Tryptophan 52.0 43.1 72.0 54.1 0.191 − 27.8 − 0.41
Leucine 60.0 40.9 44.0 15.5 0.120 36.4 0.52
Phenylalanine 52.0 24.0 42.0 15.2 0.096 23.8 0.50
Isoleucine 52.0 38.4 44.0 15.5 0.413 18.2 0.27
Cysteine 54.0 45.6 72.0 58.7 0.447 − 25.0 − 0.34
Tyrosine 58.0 36.7 46.0 15.5 0.233 26.1 0.43
Total BCAA 66.0 42.7 54.0 39.6 0.458 22.2 0.29
Total EAA 60.0 40.9 54.0 39.6 0.689 11.1 0.15
Total amino acids 58.0 43.1 60.0 52.0 0.910 − 3.3 − 0.04
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located in the gut, and probiotic supplementation has been
shown to promote a healthy immune response [25]. Studies
in athletes have shown to improve immune health by reducing
the number of episodes, severity, and duration of upper respi-
ratory tract infections following intense, prolonged exercise
[29].
Pea and rice protein are both incomplete proteins [19].
While rice protein is low in lysine, pea protein is low in me-
thionine and cysteine. Most commercial plant protein prod-
ucts combine pea and rice protein to create a plant protein
blend matching the requirements of a complete protein, as rice
protein has higher contents of methionine and cysteine, and
pea protein is rich in lysine. The co-administration of
probiotics with pea protein increased methionine AUC levels
by 20% in our study, offering an alternative nutritional ap-
proach to overcome the lowmethionine content in pea protein.
The increase in appearance in the blood of sulfur-containing
amino acids might have an additional health benefit. While
carbohydrate fermentation is linked to beneficial health effects
on the host due to the generation of short-chain fatty acids,
protein fermentation, which mainly occurs in the distal colon,
has been linked to the production of metabolites such as sul-
fides, amines, or ammonia [30]. Thus, increased absorption of
sulfur-containing amino acids by the host might reduce the
formation of sulfides.
Limitation of our study was the lack of urine and fecal
analysis to confirm improved protein retention. Plasma con-
centration of amino acids does not directly relate to muscle
protein synthesis or breakdown, which would need to be de-
termined by muscle biopsies. The in vitro analysis of “protein
hydrolysis” under small intestinal conditions is not reflective
of the in vivo response as probiotics function predominately in
the large intestine. Future studies should investigate the effects
on animal proteins.
Conclusion
In conclusion, results from the present study indicate that co-
administration of plant protein with a multi-strain probiotic
can increase post-prandial changes in blood amino acids in-
cluding EAAs and BCAAs, which are closely linked to opti-
mization of muscle health. Probiotic supplementation can be
an important nutritional strategy to overcome compositional
shortcomings of plant proteins.
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